source
- Cardiovascular biotech Kardigan raises $400M in IPO, fourth 2026 $400M+ offeringKardigan, a cardiovascular drug startup, priced a $400 million initial public offering on Wednesday, adding to a recent surge in large biotech offerings. The company becomes the fourth biotech in…
- UniQure plans to file Huntington’s disease gene therapy with FDA after leadership shift eases data requirementsUniQure, a Dutch biotech, announced it will seek FDA approval for its gene therapy targeting Huntington’s disease later this summer. The company said FDA staff indicated that three years of data f…